Maryland State Retirement & Pension System Acquires 579 Shares of Edwards Lifesciences Corporation $EW

Maryland State Retirement & Pension System raised its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 2.1% during the second quarter, Holdings Channel.com reports. The fund owned 27,974 shares of the medical research company’s stock after purchasing an additional 579 shares during the period. Maryland State Retirement & Pension System’s holdings in Edwards Lifesciences were worth $2,188,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Aurora Investment Managers LLC. bought a new position in Edwards Lifesciences in the second quarter valued at approximately $212,000. Spectrum Asset Management Inc. NB CA boosted its position in shares of Edwards Lifesciences by 1.4% during the second quarter. Spectrum Asset Management Inc. NB CA now owns 39,083 shares of the medical research company’s stock worth $3,057,000 after purchasing an additional 540 shares in the last quarter. Mirova US LLC boosted its position in shares of Edwards Lifesciences by 56.2% during the second quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock worth $229,257,000 after purchasing an additional 1,054,301 shares in the last quarter. BankPlus Trust Department boosted its position in shares of Edwards Lifesciences by 3.4% during the second quarter. BankPlus Trust Department now owns 11,907 shares of the medical research company’s stock worth $931,000 after purchasing an additional 391 shares in the last quarter. Finally, Shell Asset Management Co. boosted its position in shares of Edwards Lifesciences by 45.1% during the second quarter. Shell Asset Management Co. now owns 61,172 shares of the medical research company’s stock worth $4,784,000 after purchasing an additional 19,014 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Truist Financial lifted their price target on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the stock a “hold” rating in a research report on Friday, July 25th. Daiwa America raised shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 29th. Robert W. Baird lifted their price target on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Friday, July 25th. Oppenheimer lowered shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday. Finally, William Blair upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $87.06.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider owned 206,900 shares in the company, valued at $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Down 1.6%

Shares of EW stock opened at $74.02 on Friday. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 1 year low of $64.89 and a 1 year high of $83.00. The firm’s fifty day moving average price is $78.09 and its two-hundred day moving average price is $76.10. The firm has a market capitalization of $43.46 billion, a P/E ratio of 10.65, a PEG ratio of 3.61 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the previous year, the business earned $0.70 EPS. The company’s revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.